Company: MDXG
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001376339-25-000009
Chunk: 33

Company: MIMEDX GROUP, INC.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 33
---
Exercised(207,686)6.79 Unvested options forfeited— — Vested options expired(123,334)7.17 Outstanding at December 31, 20244,055,526 4.21 5.1621,952 Exercisable at December 31, 2024341,000 $4.21 4.87$1,851 With the exception of the CEO Performance Option (as defined and explained below), all options granted during the years ended December 31, 2024 and 2023 were valued using a Black-Scholes model. The below table reflects the material inputs used to value the options granted during those periods (exclusive of the CEO Performance Option).Year ended December 31,20242023Stock price on grant date$8.63 $6.44 Exercise price$8.63 $6.44 Expected term (years)4.754.75Risk-free interest rate4.2 %4.3 %Expected volatility (annualized)66 %77 %Dividend yield— %— %Weighted average grant date fair value$4.93 $4.10 There were no options granted during the year ended December 31, 2022.The intrinsic values of the options exercised during the years ended December 31, 2024, 2023, and 2022 were $0.2 million, $0.2 million, and $0.6 million, respectively. Cash received from option exercise under all share-based payment arrangements for the years ended December 31, 2024, 2023, and 2022 was $1.4 million, $1.0 million, and $0.7 million, respectively. The actual tax benefit for the tax deductions from option exercise of the share-based payment arrangements totaled $0.1 million, 

F- 27

$0.2 million, and $0.2 million, respectively, for the years ended December 31, 2024, 2023, and 2022. The Company has a policy of using its available repurchased treasury stock, if any, to satisfy option exercises prior to the issuance of new shares of common stock.  There was $3.4 million unrecognized compensation expense related to unvested stock options at December 31, 2024, which is expected to be recognized over 2.33 years.Restricted